Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 10 versus VASOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 10 versus VASOCIDIN.
BLEPH-10 vs VASOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolate, thereby inhibiting bacterial folic acid synthesis and exerting bacteriostatic activity.
Vasocidin is a combination of sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth, and prednisolone sodium phosphate, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and subsequent prostaglandin and leukotriene synthesis.
Instill 1-2 drops into the conjunctival sac every 3-4 hours, initially up to every 2 hours for severe infections.
One drop of the ophthalmic suspension into the conjunctival sac of the affected eye(s) every 4 hours while awake and at bedtime for 7 days; duration may be extended based on clinical response.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment.
Renal excretion of unchanged drug accounts for approximately 50-70% of the dose; biliary/fecal excretion is minimal (<10%).
Renal: 70-80% as unchanged drug; biliary/fecal: 20-30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination